XML 251 R62.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Liability Related to the Sale of Future Royalties - Narrative (Details) - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | ---
Nov. 30, 2022 | Dec. 31, 2024 | Jun. 30, 2024 | Sep. 30, 2024
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Milestone payment received |  | $ 0 |  | $ 50,000
Royalty Pharma Agreement |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Upfront payment received | $ 250,000 |  |  |
Milestone payment receivable | 160,000 |  |  |
Milestone payment receivable upon FDA approval | 50,000 |  |  |
Milestone payment receivable upon receipt of royalty payments | 60,000 |  |  |
Royalty payment threshold | 70,000 |  |  |
Milestone payment received |  |  | $ 50,000 |
Liability related to the sale of future royalties, interest rate |  | 6.30% |  |
Royalty Pharma Agreement | Amgen Incorporated |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Milestone payment receivable upon achievement of enrollment in phase 3 clinical trial |  | $ 50,000 |  |
Maximum | Royalty Pharma Agreement |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Initial transaction price | $ 410,000 |  |  |

X
- Definition Initial transaction price. + References No definition available. + Details
Name: | arwr_InitialTransactionPrice
Namespace Prefix: | arwr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Liability, Sale Of Future Royalties, Interest Rate + References No definition available. + Details
Name: | arwr_LiabilitySaleOfFutureRoyaltiesInterestRate
Namespace Prefix: | arwr_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Milestone Payment Receivable + References No definition available. + Details
Name: | arwr_MilestonePaymentReceivable
Namespace Prefix: | arwr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Milestone Payment Receivable, Upon Achievement of Enrollment in Phase 3 Clinical Trial + References No definition available. + Details
Name: | arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial
Namespace Prefix: | arwr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Milestone Payment Receivable, Upon FDA Approval + References No definition available. + Details
Name: | arwr_MilestonePaymentReceivableUponFDAApproval
Namespace Prefix: | arwr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Milestone Payment Receivable, Upon Receipt Of Royalty Payments + References No definition available. + Details
Name: | arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments
Namespace Prefix: | arwr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Milestone Payment Received, Liability Related To Sale Of Future Royalties + References No definition available. + Details
Name: | arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties
Namespace Prefix: | arwr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Royalty Payment Threshold + References No definition available. + Details
Name: | arwr_RoyaltyPaymentThreshold
Namespace Prefix: | arwr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Upfront Payment Received, Liability Related To Sale Of Future Royalties + References No definition available. + Details
Name: | arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties
Namespace Prefix: | arwr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arwr_RoyaltyPharmaAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=arwr_AmgenIncorporatedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |